UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015

Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)

2018

Volltextzugriff (PDF)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International journal of infectious diseases, 2021-12, Vol.113, p.279-281

2021

Volltextzugriff (PDF)

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis

International journal of infectious diseases, 2021-06, Vol.107, p.69-71

2021

Volltextzugriff (PDF)

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)

Journal of antimicrobial chemotherapy, 2017-05, Vol.72 (5), p.1386-1395

2017

Volltextzugriff (PDF)

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

Diagnostic microbiology and infectious disease, 2018-09, Vol.92 (1), p.69-74

2018

Volltextzugriff (PDF)

In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria

Antimicrobial agents and chemotherapy, 2022-05, Vol.66 (5), p.e0013922-e0013922

2022

Volltextzugriff (PDF)

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

Antibiotics (Basel), 2022-09, Vol.11 (9), p.1201

2022

Volltextzugriff (PDF)

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Volltextzugriff (PDF)

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014–2016

Journal of global antimicrobial resistance., 2020-03, Vol.20, p.118-123

2020

Volltextzugriff (PDF)

In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018

Journal of global antimicrobial resistance., 2021-06, Vol.25, p.14-17

2021

Volltextzugriff (PDF)

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Journal of antimicrobial chemotherapy, 2022-09, Vol.77 (10), p.2642-2649

2022

Volltextzugriff (PDF)

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18

Journal of antimicrobial chemotherapy, 2020-10, Vol.75 (10), p.2907-2913

2020

Volltextzugriff (PDF)

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)

Diagnostic microbiology and infectious disease, 2023-01, Vol.105 (1), p.115820-115820, Article 115820

2023

Volltextzugriff (PDF)

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16

Journal of antimicrobial chemotherapy, 2018-10, Vol.73 (10), p.2748-2756

2018

Volltextzugriff (PDF)

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme

International journal of antimicrobial agents, 2019-05, Vol.53 (5), p.637-643

2019

Volltextzugriff (PDF)

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Volltextzugriff (PDF)

Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

Antimicrobial agents and chemotherapy, 2020-04, Vol.64 (5)

2020

Volltextzugriff (PDF)

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Volltextzugriff (PDF)

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

Antimicrobial agents and chemotherapy, 2019-01, Vol.63 (1)

2019

Volltextzugriff (PDF)

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5‑Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA

Journal of medicinal chemistry, 2021-10, Vol.64 (20), p.15214-15249

2021

Volltextzugriff (PDF)

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)

2018

Volltextzugriff (PDF)

Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015)

The Pediatric infectious disease journal, 2018-06, Vol.37 (6), p.549-554

2018

Volltextzugriff (PDF)

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Diagnostic microbiology and infectious disease, 2022-07, Vol.103 (3), p.115713-115713, Article 115713

2022

Volltextzugriff (PDF)

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

Journal of antimicrobial chemotherapy, 2020-06, Vol.75 (6), p.1518-1524

2020

Volltextzugriff (PDF)

Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride

Diagnostic microbiology and infectious disease, 2017-12, Vol.89 (4), p.305-309

2017

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(171)
Mit Volltextzugriff
(158)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(189)

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Life Sciences & Biomedicine
(89)
Humans
(68)
Infectious Diseases
(33)
Microbiology
(31)
Female
(28)
Male
(28)
Pharmacology & Pharmacy
(25)
Biological And Medical Sciences
(24)
Medical Sciences
(20)
Adult
(19)
Animals
(15)
Microbial Sensitivity Tests
(15)
Anti-Bacterial Agents - Pharmacology
(14)
Middle Aged
(14)
Abstracts
(12)
Aged
(12)
Oncology
(11)
General & Internal Medicine
(9)
Mice
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014–2016

In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5‑Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015)

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride

Suchergebnisse filtern